|

Dual-target CAR-NK cell product Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Beijing Biotech1

Indications

  • Recurrent or Refractory Disease After Standard Therapies1
  • Primary Peritoneal Carcinoma1
  • Fallopian Tube Carcinoma1
  • Epithelial Ovarian Cancer1
  • Cancer1

Other1 trial

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.